• 08 Jul 2025
• Admin
• News Article

Fresenius Medical Care Partners with CCINSHAE to Expand Dialysis Access in Mexico

Overview

Fresenius Medical Care (FME), the world’s leading provider of products and services for individuals with renal diseases, will extend High-Volume Hemodiafiltration (HighVolumeHDF) access for patients in seven out of 10 centers in Mexico, by partnering with the country’s Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to develop a pilot programme that provides low-income patients without medical coverage in Mexico with access to hemodialysis therapies.

The contract signing

Fresenius Medical Care Mexico and CCINSHAE signed a two-year contract to enable the installation of the Fresenius Medical Care 5008S CorDiax technology in participating renal treatment centers in CCINCSHAE Centers in Mexico City (CDMX) and its metropolitan area, for a total of 150 systems in all.

Words from Edgar Robles: Executives from Fresenius Medical Care

“The groundbreaking pilot program, with its mission to provide chronic kidney disease patients with access to high quality treatments that were previously out of their reach, represents an important advancement in CKD in Mexico,” said Edgar Robles, Fresenius Medical Care Mexico’s Managing Director of Care Enablement Commercial Operations.
“Fresenius Medical Care is committed to providing access to innovative therapies such as HighVolumeHDF,” continued Robles. “Our approach is to raise quality standards in dialysis, which also improves the quality of life of patients, and simplifies operational procedures and provides efficient haemodialysis solutions for healthcare professionals.”    

Technology benefits

This technology provides standard hemodialysis as well as HighVolumeHDF, a therapy that has demonstrated improved patient well-being while increasing cost-effectiveness in most health care systems.

Fresenius and CCINSHAE Expand HighVolumeHDF to Uninsured Patients in Mexico

• The initiative between Fresenius Medical Care and the CCINSHAE has recently provided HighVolumeHDF treatment to 240 new CCINSHAE patients who do not have public or private medical coverage. 
• Further 410 regular patients, who are covered by public or private medical insurance, already started receiving HighVolumeHDF last year.
• Some of these patients were part of the hemodialysis (HD) program in CCINSHAE centers and transitioned to HighVolumeHDF, while others were new patients assigned to CCINSHAE centers for various reasons, including new diagnoses, transitions from peritoneal dialysis to hemodiafiltration or patients entering the transplant program, thus doubling the number of patients via these other sources.  

About High-Volume Hemodiafiltration

• High-Volume Hemodiafiltration is backed by multiple clinical studies, including the international, randomized and controlled CONVINCE1 Trial, which compares high-volume hemodiafiltration with standard high-flux haemodialysis. 
• The study reported a 23% reduction rate on average of all-cause mortality for patients treated with High-Volume Hemodiafiltration compared to those treated with the more commonly used high-flux haemodialysis.  
• In the Americas, Fresenius Medical Care’s HighVolumeHDF therapy is currently used in Argentina, Brazil, Canada, Caribbean Islands, Chile, Colombia, Ecuador, Mexico, Panama, Peru, and Uruguay.

Future goals for HighVolumeHDF therapy

• In the future, the company wants to bring HighVolumeHDF therapy – already widely used in Europe, Latin America, and Asia Pacific – for people living with kidney diseases in the US.
• In February 2024, Fresenius Medical Care announced it was the first company to receive US Food and Drug Administration (FDA) 510(k) clearance of the company’s 5008X Haemodialysis System.

FDA Clears 5008X CAREsystem for U.S. Launch of Advanced Hemodiafiltration Platform

In May 2025, the company received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company’s broader commercialization efforts across the US later this year, followed by a full-scale commercial launch in 2026.

Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) is part of the Public Healthcare system in Mexico (Comisión Coordinadora de Institutos Nacionales de Salud y Hospitales de Alta Especialidad).

About the company: Fresenius Medical Care

• Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. 
• Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe.